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However,previousstudiessuggesthatcircadianrhythmsofphysiological
processesare lostwithhospitalization- dueto a disruptanceof the normal
sleep-wakeor rest-activitycycles.
To determineif postoppatients(pts) maintainthe circadianvariability
of prothrcmboticforcesand catacholamlnesurgeswith an increasedAM
Incidenceof silentischemia(S1),westudied51ptswithMonaracontinuous
12-leadECGSfor 46 hra after vascularsurgery;drawingblood samples
before(dayO),& 12,24, 36, 48 hm,and7 daysaftersurgery.Timeof day
wasanalyzedas8 hr Intetvals.
r7eauffs:30% had S1within48 hra of surgery.The majority,69%, had
an AM onset (l-9 am) vs 31% expectedif time of onsetwas uniformly
distributedthroughout the day (p < 0.05).Pfswith S1had T plasminogen
activatorinhibitor(PAI-1)(26 V$ 19 rig/ml,p < 0.05)and norepinephrine
(1406vs971pg/ml,p < 0.05)vsptswithoutS1.
Conclusions:Despitehospitalization,surgicalptsmaintaincircadianvari.
abilitywith an AM peak in onsetof postopS1,correlatingwith surgesin










Tostudythe effectof therapywith b-blockerson the parioparativecardiac
mortalityof patientsundergoingmajorvascularsurgery,we retrospectively
studied420 patientsconsecutivelyreferredfor nuclearcardiologytesting
prior to vascularsurgeryat the MassachusettsGeneralHospitai,and the
Universityof Vermontbetween1964and 1991.Therewere 138patients
whoreceivedparioparativeb-blockers(BB)(32.9%).Patientson BEheda
highar inoidenceof angina(40%vs. 16%;p -=0.001)andreversibledefects
‘on preoperativestressthalliumtesting(35%vs. 23%; p = 0.01).Despite
thishigherriskprofile,the cardiacdeathrateperloperativelywasO%for BB
patients,vs.4%for nonb-blocker(NBB)patienta,respectively,(p= 0.019).
Usinga multivariateanalysis,both hx of Ml and presencaof reversible
thalliumdefectswerepredictiveof perioperetlvecardiacdeath(p a 0.001)
(n = 420). In these high risk groupa,b-blockerusa was associatedwith
pmtactionagainstdeath.Ratesof parioparativecardiacdeathamongthoaa
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liumdefacteon preopatreaateat.Thiseuggestathatthe associationis due
to protectiveeffectaof BB, ratherthan their associationwith morebenign
comorbidityprofilee.









Baroreffexsensitivity(BRS) isaaeessadby Phenyiephrinetest (PHE)in the
prognosticstratificationof cardiacpatients(pts).Alpha-index(u), a non-
invasivemeasureof the oversilgain of tha haartperiod-artarialpraeaure
relationshipderlvadfromspaetralanalyais,pmvadto providethesamaeeti-





mwasmeasuredaa rootaquareof the ratioRRto SAPvariabilityspectral
power(P):a =(PRH/PSAp)05,whenthemagnitudesquaredcoherence(MSC)
betweenRRandSAPvariabilitywas>0.50 in lowfrequency(0.04-0.15Hz)
(aLF)and high frequency(0.15-0.45Hz) (IYHF)bands;the meana was
mmputadaea = (aLF+ aHF)/2.PHEfollowedimmediately,by at least3
injections:BRSwasmeasuredas slopeof the regressionlinebetweenRR
andSAPchanges(ARWASAP)whenASAP> 15 mmHgand regression
coefficientr >0.70.
Results:
uLF 10.2* 4.0me’mmHg (n=24)
mHF 7.8+ 4.5mrJmmHg (n =33)
d = (aLF + aHF)/2 9.3 * 3.7 ms/mmHg (n=23)
BRS (PHE) S.7+ 4.3mdmmHa (n = 37)
tiLF wasmeasuredin 60%of pts,IXHFin 82%,a in 57%;PHEallowed
to measureBRSIn92%of pts.Weakcorrelationswereobservedbetween
BRS(PHE)andaLF(r= 0.61),crHF(r=0.S3),a (r= 0.67).Ofnote,aLF was
notevaluablein pts with BRS(PHE)<6 m4mmHgor EF < 25%.
Incmncluslon,a measuredover600heartbeatsbyspectralanalysisdid
notprovidethe sameInformationas PHEdid in our CHFpts,A proportion
of pts,with non-assessablea, hada depressedbut measurableresponse























lower lnHFthan patientswithoutCHF (3.73vs 4.16 In me2,p e 0.001).
Adjustadfor age and LVEFby multipleragreaaion,lnHFwas0.37 In ms2
lower,on average,in patientswithCHFthanin patiantawithoutCHF,(p <




CHFis associatedwitha reductionin PSNAavanafteradjuatingfor LVEF.










analysisof variabilityof haartrate (HRV)and eyatolicbloodpreaaurewaa
performedin 12 patientewith CHFat baseline(B) and one (1 mo) and 4
months(4mo)of traatmantwithcarvediiol.Significant(p = 0.007)increaaes
inparasympathetic(pare)tonewerereflectedbyincreasesin highfrequency
HRV(baata/min)2(B: 1.3 x 10-3+ 0.8 x 10-3; 1 mo: 1.9 x 10-3 & 1.0 x
10”3;4 mo:2.2 x 10-3+ 0.7 x 10-s).Sympathetic(symp)tonadecreaaad
